Zobrazeno 1 - 10
of 396
pro vyhledávání: '"James A. Harding"'
Autor:
Ghassan K. Abou-Alfa, Tim Meyer, Richard Kinh Gian Do, Sarina A. Piha-Paul, Joseph S. Light, Scott Sherrin, Amin Yaqubie, Alison Clemens O’Neill, James J. Harding, Raed Al-Rajabi, Crystal S. Denlinger, Pablo Cano, Albert S. Cornelius, Eileen M. O'Reilly, Daniel DiPrimeo, Lisa D. Eli, John D. Gordan, David B. Solit
Publikováno v:
Liver Cancer, Pp 1-10 (2024)
Introduction: Fibrolamellar carcinoma (FLC) displays upregulation of several oncogenes, including HER2, and multiple immune-suppressive mechanisms. We investigated the efficacy and safety of the pan-HER tyrosine kinase inhibitor neratinib as monother
Externí odkaz:
https://doaj.org/article/060277f2d7054affa161c9c60698ca95
Autor:
Sebastián Mondaca, Henry Walch, Santiago Sepúlveda, Nikolaus Schultz, Gonzalo Muñoz, Amin Yaqubie, Patricia Macanas, Claudia Pareja, Patricia Garcia, Walid Chatila, Bruno Nervi, Bob Li, James J. Harding, Paola Viviani, Juan Carlos Roa, Ghassan K. Abou-Alfa
Publikováno v:
JCO Global Oncology, Iss 10 (2024)
PURPOSEGallbladder cancer (GBC) is a biliary tract malignancy characterized by its high lethality. Although the incidence of GBC is low in most countries, specific areas such as Chile display a high incidence. Our collaborative study sought to compar
Externí odkaz:
https://doaj.org/article/3e177846e0ea4a48b47dc3c144723c3a
Autor:
Ken Zhao, Sam Son, Anita Karimi, Brett Marinelli, Joseph P. Erinjeri, Erica S. Alexander, Vlasios S. Sotirchos, James J. Harding, Kevin C. Soares, Etay Ziv, Anne Covey, Constantinos T. Sofocleous, Hooman Yarmohammadi
Publikováno v:
Current Oncology, Vol 31, Iss 5, Pp 2650-2661 (2024)
The aim of this study was to evaluate outcomes of transarterial radioembolization (TARE) for hepatocellular carcinoma (HCC) in patients previously treated with transarterial embolization (TAE). In this retrospective study, all HCC patients who receiv
Externí odkaz:
https://doaj.org/article/6d48e7c924344550a3c553ce5fb0a3bd
Autor:
Sara Velayati, Ahmed Elsakka, Ken Zhao, Joseph P. Erinjeri, Brett Marinelli, Mohamed Soliman, Olivier Chevallier, Etay Ziv, Lynn A. Brody, Constantinos T. Sofocleous, Stephen B. Solomon, James J. Harding, Ghassan K. Abou-Alfa, Michael I. D’Angelica, Alice C. Wei, Peter T. Kingham, William R. Jarnagin, Hooman Yarmohammadi
Publikováno v:
Current Oncology, Vol 30, Iss 10, Pp 9181-9191 (2023)
The safety and efficacy of hepatic artery embolization (HAE) in treating intrahepatic cholangiocarcinoma (IHC) was evaluated. Initial treatment response, local tumor progression-free survival (L-PFS), and overall survival (OS) were evaluated in 34 IH
Externí odkaz:
https://doaj.org/article/7cbeab7a43d54e31aadc95f47c6af60a
Autor:
Kevin C. Soares, Joshua S. Jolissaint, Sarah M. McIntyre, Kenneth P. Seier, Mithat Gönen, Carlie Sigel, Naaz Nasar, Andrea Cercek, James J. Harding, Nancy E. Kemeny, Louise C. Connell, Bas Groot Koerkamp, Vinod P. Balachandran, Michael I. D'Angelica, Jeffrey A. Drebin, T. Peter Kingham, Alice C. Wei, William R. Jarnagin
Publikováno v:
Cancer Medicine, Vol 12, Iss 11, Pp 12272-12284 (2023)
Abstract Purpose The role of locoregional therapy compared to systemic chemotherapy (SYS) for unresectable intrahepatic cholangiocarcinoma (IHC) remains controversial. The importance of hepatic disease control, either as initial or salvage therapy, i
Externí odkaz:
https://doaj.org/article/9431db9eb6cc4c9cbb73944c832e818f
Autor:
James J. Harding, Sarina A. Piha-Paul, Ronak H. Shah, Jessica J. Murphy, James M. Cleary, Geoffrey I. Shapiro, David I. Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James M. Ford, Mónica Arnedos, Salomon M. Stemmer, Christelle de la Fouchardiere, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S. Duygu Selcuklu, Michael F. Berger, Lisa D. Eli, Funda Meric-Bernstam, Komal Jhaveri, David B. Solit, Ghassan K. Abou-Alfa
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
In biliary tract cancer HER2 alterations correlate with poor prognosis. Here, the authors present the results of a phase II clinical trial reporting the efficacy and safety of the tyrosine kinase inhibitor neratinib in patients with HER2-mutation pos
Externí odkaz:
https://doaj.org/article/6b0c6dc798b14d37bd9664bd41aec7e1
Autor:
Dazhi Liu, Michael A. Weintraub, Christine Garcia, Marcus D. Goncalves, Ann Elizabeth Sisk, Alissa Casas, James J. Harding, Stephen Harnicar, Alexander Drilon, Komal Jhaveri, James H. Flory
Publikováno v:
Cancer Medicine, Vol 11, Iss 8, Pp 1796-1804 (2022)
Abstract Purpose The phosphoinositide 3‐kinase (PI3K)/protein kinase B (AKT) pathway controls insulin sensitivity and glucose metabolism. Hyperglycemia is one of the most common on‐target adverse effects (AEs) of PI3K/AKT inhibitors. As several P
Externí odkaz:
https://doaj.org/article/6261ca0f91da4aafad9291fcc66547c9
Autor:
Perla Chami, Youssef Diab, Danny N. Khalil, Hassan Azhari, William R. Jarnagin, Ghassan K. Abou-Alfa, James J. Harding, Joseph Hajj, Jennifer Ma, Maria El Homsi, Marsha Reyngold, Christopher Crane, Carla Hajj
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 23, p 16773 (2023)
The liver tumor immune microenvironment has been thought to possess a critical role in the development and progression of hepatocellular carcinoma (HCC). Despite the approval of immune checkpoint inhibitors (ICIs), such as programmed cell death recep
Externí odkaz:
https://doaj.org/article/2ebfd17f8169434db54d7829f88974ae
Autor:
A. Rose Brannon, Gowtham Jayakumaran, Monica Diosdado, Juber Patel, Anna Razumova, Yu Hu, Fanli Meng, Mohammad Haque, Justyna Sadowska, Brian J. Murphy, Tessara Baldi, Ian Johnson, Ryan Ptashkin, Maysun Hasan, Preethi Srinivasan, Anoop Balakrishnan Rema, Ivelise Rijo, Aaron Agarunov, Helen Won, Dilmi Perera, David N. Brown, Aliaksandra Samoila, Xiaohong Jing, Erika Gedvilaite, Julie L. Yang, Dennis P. Stephens, Jenna-Marie Dix, Nicole DeGroat, Khedoudja Nafa, Aijazuddin Syed, Alan Li, Emily S. Lebow, Anita S. Bowman, Donna C. Ferguson, Ying Liu, Douglas A. Mata, Rohit Sharma, Soo-Ryum Yang, Tejus Bale, Jamal K. Benhamida, Jason C. Chang, Snjezana Dogan, Meera R. Hameed, Jaclyn F. Hechtman, Christine Moung, Dara S. Ross, Efsevia Vakiani, Chad M. Vanderbilt, JinJuan Yao, Pedram Razavi, Lillian M. Smyth, Sarat Chandarlapaty, Gopa Iyer, Wassim Abida, James J. Harding, Benjamin Krantz, Eileen O’Reilly, Helena A. Yu, Bob T. Li, Charles M. Rudin, Luis Diaz, David B. Solit, Maria E. Arcila, Marc Ladanyi, Brian Loomis, Dana Tsui, Michael F. Berger, Ahmet Zehir, Ryma Benayed
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Liquid biopsies allow the non-invasive detection of somatic mutations from tumours. Here, the authors develop and test MSK-ACCESS, an NGS-based clinical assay for identifying low frequency mutations in 129 genes and describe how it benefits patients
Externí odkaz:
https://doaj.org/article/ca7c61a9651341a5819f1ee6a4c47bfa
Autor:
James J. Harding, Richard K. Do, Amin Yaqubie, Ann Cleverly, Yumin Zhao, Ivelina Gueorguieva, Michael Lahn, Karim A. Benhadji, Robin K. Kelley, Ghassan K. Abou‐Alfa
Publikováno v:
Cancer Medicine, Vol 10, Iss 9, Pp 3059-3067 (2021)
Abstract Background Preclinical data suggest that vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)‐β signaling interact to stimulate angiogenesis and suppress antitumor immune responses. Thus, combined inhibition of b
Externí odkaz:
https://doaj.org/article/a3e937bb75b74d4cbd5609cb1c0768da